News

The safety and efficacy of Xanamem is currently being studied in clinical trials. Xanamem is not approved for use by the US Food & Drug Administration or any other regulatory authority.

17 Sep 2025	Courier Mail	Daily pill to treat dementia gets nod
22 Jul 2025	PR Newswire	A novel oral treatment for Alzheimer’s: Actinogen’s pivotal trial currently recruiting participants in the US
01 Jul 2025	FIVEAA	FIVEAA Adelaide radio interview with Dr Steven Gourlay on once-a-day Alzheimer’s pill [8m 25s]
30 Jun 2025	Nine News Melbourne	Alzheimer’s trial – Melbourne hospitals play key role
30 Jun 2025	PR Newswire	Actinogen confirms 100th participant in XanaMIA phase 2b/3 Alzheimer’s disease trial and interim analysis timeline
15 May 2025	Webcast Video Recording	ACW Clinical Trials Science Forum 2025 – The critical importance of preparing for commercialization [1.00 hr]
05 Mar 2025	HotCopper	Executive Interview HotCopper with Dr Steven Gourlay: Xanamem: Alzheimer’s breakthrough set for 2025, 2026
12 Feb 2025	PR Newswire	Actinogen announces peer-reviewed clinical pharmacology manuscript for Xanamem (emestedastat) published in Clinical Pharmacology in Drug Development journal
05 Feb 2025	PR Newswire	Actinogen announces new and unique nonproprietary name of ’emestedastat’ for Xanamem
05 Feb 2025	ABC Radio	Audio Recording: ABC Radio Melbourne interview with Dr Steven Gourlay (3m 28s)
05 Feb 2025	10 First News	Executive Interview: 10 First News with Dr Steven Gourlay
24 Jan 2025	Actinogen	Executive Interview: Edison Group interviews Dr Steven Gourlay (23m39s)
12 Jan 2025	Actinogen	Video recording: Actinogen Medical at the Sachs Neuroscience Innovation Forum 2025 (17m: 44s)
06 Jan 2025	Daily Mail Online	Hopes new drug likened to ‘exercise in a pill’ will deal a major blow against Alzheimer’s
09 Dec 2024	PR Newswire	Actinogen randomizes first US participant in XanaMIA phase 2b/3 Alzheimer’s disease trial
18 Sep 2024	Actinogen	Webcast Video Recording: ACW $11.1 capital raising
30 Aug 2024	Actinogen	Webcast Video Recording: Actinogen updated Depression Trial results and implications presentation
26 Aug 2024	PR Newswire	Actinogen announces further positive results on depression in the XanCIDD phase 2a trial
12 Aug 2024	Actinogen	Webcast Video Recording: Actinogen XanaCIDD topline results presentation
12 Aug 2024	PR Newswire	Actinogen announces achievement of clinically and statistically significant superiority of Xanamem® over placebo on depression in XanaCIDD phase 2a trial
26 Jun 2024	PR Newswire	Positive Xanamem® biomarker trial published in the Journal of Alzheimer’s Disease demonstrating potential Xanamem efficacy in patients with elevated blood pTau
03 Jun 2024	Actinogen	Video Recording: ACW Australian Dementia Research Forum poster presentation
24 May 2024	Actinogen	Webcast Video Recording: Actinogen Clinical Trials Science Forum 2024 – Pipeline in a Pill
06 May 2024	Actinogen	Video interview: [2:49 mins] Market Link interview with ACW CEO, Steven Gourlay
03 May 2024	Corporate Presentations	Video Presentation: Actinogen May 2024 $8.9m capital raising webinar
22 Apr 2024	PR Newswire	Enrolment completed in Actinogen’s XanaCIDD phase 2a cognition & depression trial
15 Apr 2024	PR Newswire	First patient treated in Actinogen’s XanaMIA phase 2b Alzheimer’s disease trial
24 Jan 2024	PR Newswire	Positive Xanamem® human PET study published in the Journal of Alzheimer’s Disease demonstrating robust CNS target enzyme occupancy
08 Jan 2024	Corporate Presentations	Company Presentation: ACW CEO & CMO present at Sachs Neuroscience Innovation Forum & JPM week meetings
07 Jan 2024	Corporate Presentations	Video Presentation: ACW CMO presents at Sachs Neuroscience Innovation Forum
28 Nov 2023	PR Newswire	Actinogen XanaCIDD Phase 2a trial in patients with depression and cognitive impairment: enrolment accelerating and on track for results in second quarter of 2024
15 Nov 2023	Corporate Presentations	Company Presentation: ACW CEO presents at Bell Potter Healthcare Conference 2023
25 Oct 2023	Corporate Presentations	Company Presentation: ACW CMO presents academic poster at CTAD 2023 conference
18 Oct 2023	Corporate Presentations	Company Presentation: ACW CEO presentation for meetings at BIO Investor Forum USA
13 Oct 2023	PR Newswire	Actinogen to present progress on Phase 2 trials at the BIO Investor Forum, San Francisco and Clinical Trials on Alzheimer’s Disease (CTAD) Conference, Boston
06 Oct 2023	Actinogen	Company Presentation: ACW CEO presents to Dementia Trials Australia conference
29 Sep 2023	Actinogen	Company Presentation: ACW Clinical Scientist presents to the Asian Society Against Dementia congress
26 Sep 2023	PR Newswire	Actinogen optimizes XanaMIA Phase 2b Alzheimer’s disease trial design and provides general business update
14 Sep 2023	Actinogen	Video interview: [14.46 mins] Xanamem program update
31 Aug 2023	Media	Webcast video recording: Actinogen neuroscience webinar
07 Jun 2023	PR Newswire	Actinogen to present progress on Cognitive Impairment in Depression and Alzheimer’s Disease Phase 2 trials at the BIO International Convention
05 Jun 2023	Media	Insight: Beyond the amyloid hypothesis – how small molecules are giving hope to Alzheimer’s research
31 May 2023	PR Newswire	Actinogen to present progress on Cognitive Impairment in Depression and Alzheimer’s Disease Phase 2 trials at the BIO International Convention
24 May 2023	Actinogen	Webcast video recording: Actinogen Clinical Trials Science Forum 2023
30 Mar 2023	PR Newswire	Actinogen presents positive Phase 2a Xanamem data at AD/PD™ Alzheimer’s and Parkinson’s diseases conference
30 Mar 2023	Actinogen	Oral presentation: CMO presentation at Alzheimer’s and Parkinson’s Disease Conference (AD/PD™) in Gothenburg, Sweden
01 Mar 2023	Biotech Daily	Actinogen Appoints Nicki Vasquez Non-Executive Director
24 Feb 2023	Actinogen	Company presentation: Spark Plus Biotech Conference in Singapore
01 Feb 2023	Biotech Daily	Actinogen Appoints Dr Dana Hilt CMO
09 Jan 2023	Actinogen	Company presentation: Sachs Neuroscience Innovation Forum and other meetings during the JP Morgan Healthcare Conference week